2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4695 Benefits of vitd replacement in adults with sickle cell disease (SCD)

Ashwin Prahladbhai Patel, MBBS, PhD, Vivien A Sheehan, MD,PhD2
1 Emory University School of Medicine, Atlanta, Georgia, United States
2 Emory University School of Medicine, Atlanta, Georgia, United States

Background: Sickle cell disease (SCD) is the most common genetic disorder in the USA affecting ~ 100,000 individuals. Individuals with SCD experience significant morbidity and shortened lifespan, causing a significant public health burden. Thus, maintenance therapies, including replacement of micronutrients, need to be optimized. Vitamin D (vitD) replacement is critical due to its high deficiency rates (~ 95%) and association with SCD-related complications. Research supports HbF induction by vitD; vitD is shown to increase expression of Insulin-like Growth Factor Binding Protein 3 expression (IGFBP3). Further, using erythroid culture our team demonstrated that IGFBP3 induces HbF via FOXO3 pathway. We also reported a positive association between vitD and HbF levels and reduced opioid use in a retrospective pediatric SCD cohort. However, the benefits of vitD replacement in the adult SCD population are unexplored. Current guidelines do not recommend vitD screening due to a lack of robust data on the benefits of vitD replacement, leading to poor screening and replacement rates and high vitD deficiency rates. Inadequate response to vitD replacement in ~50% of patients worsen the problem further. We report the first evaluation of laboratory biomarkers, clinical outcomes, and opioid use following vitD replacement in an adult SCD cohort.

Methods: Under an IRB approved protocol, electronic medical records from 2904 individuals with SCD receiving care in the Grady Memorial Hospital Healthcare System from 2010 to 2025 were reviewed to extract age, gender, race, genotype, and encounter-level data, including date, hemoglobin electrophoresis, vitD levels, inpatient / emergency department opioid dose in MME (morphine milligram equivalent); prescriptions for hydroxyurea (HU), vitD, and other disease-modifiers (voxelotor, crizanlizumab, L-glutamine). VitD status was classified as: deficiency (<20 ng/ml), insufficiency (<30 ng/ml), and no deficiency (≥30 ng/ml). Chronic transfusion therapy (CTT) was defined as ≥ six red cell transfusions/ year. Pain events (VOE), episodes of acute chest syndrome (ACS), and MME doses were vitD status. Mixed-effects generalized linear models analyzed the association between 1) vitD and HbF levels, and 2) MME and vitD status. Bayesian mixed-effects negative binomial regression analyzed the associations between vitD status and ACS and acute events. Post-transfusion data were excluded from HbF analysis. StataNow 19.5 was used for analyses; p<0.05 was considered significant.

Results: Mean vitD level was 10.9 ng/ml in deficient patients. Only 10 (0.3%) patients were never deficient during the period of . Eighty-one percent of patients with baseline deficiency/insufficiency did not achieve a replete status during the observation period. In the HbSS/HbSβ0 cohort, HbF was 2%-points higher in patients on HU vs no HU (P<0.001); each 10 ng/ml higher vitD level was associated with 0.45%-point higher HbF levels independent of HU therapy (P<0.001). HbF and vitD levels were not associated in the HbSC cohort (p=0.5). HbF levels were 3.5%-points lower in males than females. Opioid use decreased linearly with vitD levels: 38.3% lower consumption with insufficiency (p=0.001) and 44.8% lower with no deficiency (p<0.001) compared to vitD deficiency after adjusting for gender, age, and CTT. VitD deficient patients had a trend for lower ACS events (IRR=1.38, p=0.07) but had no association with acute events (IRR=0.88, p=0.38).

Conclusions: Our data shows significant reduction in opioid use (~50%) with correction of vitD deficiency in adults with SCD.  The modest HbF rise of 1%-point needs further investigation.  Aggressive vitD replacement and HU therapy at maximum tolerated dose may increase HbF induction and reduce SCD-related complications. Significantly lower opioid requirements even in vitD insufficiency compared to deficiency suggests benefits with even inadequate replacement. Large sample size, long follow-up period of 15 years, and advanced statistical modeling are major strengths of our study. Future studies will evaluate the impact of vitD replacement on chronic SCD-related complications.

Ashwin Prahladbhai Patel, MBBS, PhD: No relevant conflicts of interest to declare.